Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Erratum

Erratum to: Association of the germline TP53 R337H mutation with breast cancer in southern Brazil

Authors: Juliana G Assumpção, Ana Luíza Seidinger, Maria José Mastellato, Raul C Ribeiro, Gerard P Zambetti, Ramapriya Ganti, Kumar Srivastava, Sheila Shurtleff, Deqing Pei, Luiz Carlos Zeferino, Rozany M Dufloth, Silvia Regina Brandalise, José Andres Yunes

Published in: BMC Cancer | Issue 1/2011

Login to get access

Excerpt

Of the 123 patients included in our work [1], 44 were selected according to the following familial risk history criteria: early onset (less than 35 years of age); bilateral carcinoma; more than three cases of breast cancer and more than one case of ovarian cancer in the family; more than two first degree relatives involved; and male breast cancer. We regret that in the methods section of our manuscript [1], it was erroneously stated both that the number of patients with familial history was 45 and that the criteria used for their selection was: "had either more than three cases of breast cancer and more than one case of ovarian cancer in the family; or had more than two first-degree relatives with breast cancer; or had one case of male breast cancer" (only two out of these 44 patients would have fulfilled these criteria). …
Metadata
Title
Erratum to: Association of the germline TP53 R337H mutation with breast cancer in southern Brazil
Authors
Juliana G Assumpção
Ana Luíza Seidinger
Maria José Mastellato
Raul C Ribeiro
Gerard P Zambetti
Ramapriya Ganti
Kumar Srivastava
Sheila Shurtleff
Deqing Pei
Luiz Carlos Zeferino
Rozany M Dufloth
Silvia Regina Brandalise
José Andres Yunes
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-152

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine